
    
      This study aims to determine the recommended dose of the allogeneic CYAD-211 (anti-BCMA
      CAR-T) cells after a non-myeloablative preconditioning chemotherapy in multiple myeloma (MM)
      patients with relapsed or refractory disease.
    
  